Clinical trial
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
NCT00372983 · Cellectar Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00372983 |
|---|---|
| Title | Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy |
| Official title | A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin |
| Lead sponsor | Cellectar Biosciences, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | NOV-205 |
| Enrollment | 30 |
| Start date | Aug 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Sep 7, 2006 |
| Last update posted | Dec 21, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: